Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00955240|
Recruitment Status : Unknown
Verified July 2011 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : August 10, 2009
Last Update Posted : July 11, 2011
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radiation therapy together with combination chemotherapy and cetuximab may kill more tumor cells.
PURPOSE: This phase II trial is studying giving radiation therapy together with cisplatin, fluorouracil, and cetuximab to see how well it works in treating patients with locally advanced anal cancer.
|Condition or disease||Intervention/treatment||Phase|
|Anal Cancer||Biological: cetuximab Drug: cisplatin Drug: fluorouracil Other: laboratory biomarker analysis Radiation: radiation therapy||Phase 2|
- Evaluate the objective response (complete and partial) 8 weeks after completion of study treatment comprising radiotherapy, chemotherapy (fluorouracil and cisplatin), and cetuximab followed by additional radiotherapy in patients with locally advanced anal cancer.
- Evaluate colostomy-free survival.
- Evaluate the local control rate (objective response and stabilization) at 8 weeks.
- Evaluate relapse-free survival at 5 years.
- Evaluate the intermediate objective response at the end of week 5 of radiotherapy.
- Evaluate overall survival at 5 years.
- Evaluate the duration of response.
- Evaluate acute toxicities according to CTCAE v3.0.
- Evaluate late toxicities at 5 years according to CTCAE v3.0.
- Study the tumor markers associated with response (survival without relapse) and toxicity.
- Study the genotypes of Fc-receptor immunoglobulins (FCGR2A and FCGR3) and their association with skin toxicity, objective survival, and relapse-free survival.
OUTLINE: This is a multicenter study.
Patients receive cetuximab IV on days 0, 7, 14, 21, 28, and 35; fluorouracil IV on days 7-10 and 35-38; and cisplatin IV over 2 hours on days 7 and 35. Beginning on day 7, patients also undergo radiotherapy 5 days a week for 5 weeks (weeks 2-6). Two weeks after finishing this treatment, patients undergo additional radiotherapy* 5 days a week for 2 weeks (weeks 9 and 10).
NOTE: *Some patients may undergo brachytherapy.
Blood and tissue samples are collected for further analysis.
After completion of study treatment, patients are followed up for 4 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||77 participants|
|Official Title:||Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer|
|Study Start Date :||March 2009|
- Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment
- Survival rate at 3 and 5 years
- Colostomy-free survival at 3 and 5 years
- Duration of objective response
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00955240
|Bordeaux, France, 33076|
|CHU Hopital A. Morvan|
|Brest, France, 29609|
|Centre Regional Francois Baclesse|
|Caen, France, 14076|
|Centre Hospitalier Departemental|
|La Roche Sur Yon, France, F-85025|
|Centre Oscar Lambret|
|Lille, France, 59020|
|Centre Hospital Regional Universitaire de Limoges|
|Limoges, France, 87042|
|Centre Leon Berard|
|Lyon, France, 69373|
|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle|
|Montpellier, France, 34298|
|Centre Regional Rene Gauducheau|
|Nantes-Saint Herblain, France, 44805|
|Centre Antoine Lacassagne|
|Nice, France, 06189|
|Institut Curie Hopital|
|Paris, France, 75248|
|Paris, France, 75475|
|Paris, France, 75970|
|Centre Hospitalier Lyon Sud|
|Pierre Benite, France, 69495|
|Hopital Charles Nicolle|
|Rouen, France, 76031|
|Centre Hospitalier Prive Saint-Gregoire|
|Saint-Gregoire, France, 35768|
|Clinique Du Parc|
|Toulouse, France, 31078|
|Groupe Oncorad Garonne|
|Toulouse, France, 31300|
|Centre Alexis Vautrin|
|Vandoeuvre-les-Nancy, France, 54511|
|Institut Gustave Roussy|
|Villejuif, France, F-94805|
|Principal Investigator:||Eric Deutsch, MD||Gustave Roussy, Cancer Campus, Grand Paris|